medigraphic.com

2020, Number 2

Dermatol Rev Mex 2020; 64 (2)

Epidemiological data of candidiasis in a tertiary hospital in the State of Mexico

Frías-De León MG, Rodríguez-Vizcaíno AC, Torres-Páez OU, Acosta-Altamirano G, Martínez-Herrera E

Language: Español
References: 23
Page: 109-114
PDF size: 224.99 Kb.


ABSTRACT

Background: In Mexico, epidemiological data show an increase in the incidence of candidiasis; however, these data come only from some entities in the country.
Objective: To know the epidemiology of candidiasis in a third level hospital in the State of Mexico.
Material and Method: A retrospective, observational and cross-sectional study, which included all patient records that during the period from January 2013 to December 2017 had at least one positive culture for Candida spp. The variables analyzed were: variety and clinical manifestation, isolated Candida species, sex, age, comorbidities, treatment and year of hospital admission.
Results: 210 cases of superficial candidiasis were included; no cases of invasive candidiasis were found. The predominant variety was the mucocutaneous and the vulvovaginal candidiasis was the most frequent clinical manifestation, followed by balanitis, oral candidiasis and cutaneous candidiasis. The predominant causative agent was C. albicans. The main predisposing factor was diabetes mellitus type 2. Azoles were the treatment of choice.
Conclusions: The epidemiology of candidiasis in the study hospital is similar to that reported in other entities of the country; vulvovaginal candidiasis was the most frequent manifestation in women, 30-50 years of age, who have diabetes mellitus.

References

  1. Calderone RA, Clancy CJ. Candida and candidiasis. 2ª ed. Washington: ASM Press, 2011;544.

  2. Hani U, Shivakumar HG, Vaghela R, Osmani RA, Shrivastava A. Candidiasis: a fungal infection-current challenges and progress in prevention and treatment. Infect Disord Drug Targets 2015;15(1):42-52. DOI: 10.2174/1871526515666 150320162036.

  3. Reyes-Montes MR, Duarte-Escalante E, Martínez-Herrera E, Acosta-Altamirano G, Frías-De León MG. Current status of the etiology of candidiasis in Mexico. Rev Iberoam Micol 2017;34(4):203-10. doi: 10.1016/j.riam.2017.05.001.

  4. Arenas R. Micología Médica Ilustrada, 5ª ed. México, Mc GrawHill: 2014;240-260.

  5. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013;62:10-24. doi: 10.1099/jmm.0.045054-0.

  6. Martins N, Ferreira IC, Barros L, Silva S, Henriques M. Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia 2014;177(5- 6):223-40. doi: 10.1007/s11046-014-9749-1.

  7. Pineda-Murillo J, Cortés-Figueroa AA, Uribarren-Berrueta TNJ, Castañón-Olivares LR. Candidosis vaginal: Revisión de la literatura y situación de México y otros países latinoamericanos. Rev Med Risaralda 2017; 23(1): 38-44.

  8. García-Figueroa RB, Araiza-Santibáñez J, Basurto-Kuba E, Bonifaz-TrujilloA. Candida glabrata: un oportunista emergente en vulvovaginitis. Cir Cir 2009; 77: 455-60.

  9. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013;125:33-46. https:// www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org %2F10.3810%2Fpgm.2013.05.2650.

  10. Bonifaz A, Tirado-Sánchez A, Graniel MJ, Mena C, Valencia A, Ponce-Olivera RM. The efficacy and safety of sertaconazole cream (2%) in diaper dermatitis candidiasis. Mycopathologia 2013;175:249-54.

  11. Rodríguez Ortega J, Miranda Tarrago J, Morejon Lugones H, Santana Garay JC. Candidiasis de la mucosa bucal: Revisión bibliográfica. Rev Cubana Estomatol 2002;39(2):187-233.

  12. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against Candida fungal infections. Nat Rev Immunol 2015;15(10):630-42.

  13. Araiza J, Montes de Oca G, Ponce Olivera RM, Bonifaz A. Balanitis y balanopostitis candidósica. Comunicación de 20 casos. Dermatología Rev Mex 2011;55(6):342-6.

  14. Frydrych LM, Bian G, O'Lone DE, Ward PA, Delano MJ. Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol 2018; doi: 10.1002/JLB.5VMR0118-021RR.

  15. Lucas VS. Association of psychotropic drugs, prevalence of denture-related stomatitis and oral candidosis. Community Dent Oral Epidemiol 1993;21(5):313-6. DOI: 10.1111/j.1600-0528.1993.tb00782.x

  16. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2(5):372-7. doi: 10.1038/nri803.

  17. Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candida balanitis: risk factors. JEADV 2010;24:820-6. doi: 10.1111/j.1468-3083.2009.03533.x.

  18. Fischer D, Orlando PL, Shane-McWhorter L. Balanitis: A unique presentation of diabetes in an elderly male. Consult Pharm 2017;32(12): 740-7. doi: 10.4140/TCP.n.2017.740.

  19. Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001;20(2):197-206. DOI: 10.1097/00006454- 200102000-00017.

  20. Aguirre J. Candidiasis orales. Rev Iberoam Micol 2002;19:17-21.

  21. Mendiratta V, Mittal S, Jain A, Chander R. Mucocutaneous manifestations in children with human immunodeficiency virus infection. Indian J Dermatol Venereol Leprol 2010;76(5):458-66. doi: 10.4103/0378-6323.69041.

  22. Quindós G, Ribacoba L, Contreras I, Aguirre JM. Tratamiento de las candidiasis orofaríngeas. Rev Iberoam Micol 1996;13:11-5.

  23. Bondaryk M, Kurzatkowski W, Staniszewska M. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. Postepy Dermatol Alergol 2013; 30(5): 293-301. doi: 10.5114/pdia.2013.38358.

2020     |     www.medigraphic.com